Cagrilintide's cellular targets identified across rat, mouse, and macaque brainstem

Obesity remains a significant global health challenge, with current therapies often having limited efficacy or side effects. Amylin receptor agonists, such as cagrilintide, represent a promising class of emerging treatments for weight management. However, the precise cellular and neuronal populations mediating cagrilintide's therapeutic effects, particularly within key brain regions like the caudal brainstem, have been poorly understood. Identifying these specific cellular loci is crucial for optimizing drug design and therapeutic strategies.

Researchers generated a comprehensive transcriptomics atlas from over 530,000 cells across 80 distinct neuronal cell populations. This atlas was derived from the caudal brainstem of rat, mouse, and macaque models. The study employed spatial profiling techniques to precisely map the cellular loci of cagrilintide action, focusing on identifying specific cell types and regions expressing relevant receptors and downstream signaling molecules. This approach aimed to provide a detailed anatomical and molecular understanding of the drug's targets.

The study successfully identified and mapped the specific cellular loci responsible for cagrilintide action within the caudal brainstem across three distinct species. Using a high-resolution transcriptomics atlas of over 530,000 cells, researchers pinpointed 80 neuronal cell populations that exhibit expression patterns consistent with mediating the drug's effects. The identified loci span various neuronal subtypes, suggesting a complex interplay of circuits in cagrilintide's mechanism.

These identified cellular targets provide critical insights into the precise neuronal circuits engaged by cagrilintide to exert its anti-obesity effects. The spatial profiling confirmed the anatomical distribution of these key cellular populations, offering a foundational understanding of cagrilintide's mechanism of action at a cellular resolution previously unavailable, paving the way for targeted therapeutic development.